Sanofi finally manages to close on a buyout – but it’s not a game changer
Sanofi $SNY has finally managed to complete a buyout — though it’s a far cry from the kind of transformational blockbuster deal it’s been on the hunt for.
After missing out on auctions for Medivation and Actelion, the French pharma giant has snagged Protein Sciences and its quadrivalent flu vaccine Flublock, approved last fall. Sanofi is paying $650 million in cash and offering up $100 million more in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.